Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- Fizazi, K.
- Tran, N.
- Fein, L.
- Matsubara, N.
- Rodriguez-Antolin, A.
- Alekseev, B.Y.
- Özgüroğlu, M.
- Ye, D.
- Feyerabend, S.
- Protheroe, A.
- Sulur, G.
- Luna, Y.
- Li, S.
- Mundle, S.
- Chi, K.N.
ISSN: 1474-5488, 1470-2045
Argitalpen urtea: 2019
Alea: 20
Zenbakia: 5
Orrialdeak: 686-700
Mota: Artikulua